E/C/F/TAF recently approved for treatment of HIV infection,seems to be one of the most appealing combinations,due to his efficacy, durability and tolerability. The available data from clinical trials, showed challenging results about modifications in lipid profile, in particular when switching from TDF to TAF.Data deriving from real-life are missing.Aim of our study was to investigate the role of E/C/F/TAF on lipid profile, within the Italian Compassionate Use program.
Changes of lipid profile after switching to E/C/F/TAF: data from the Italian Compassionate Use Program
PELLICANO', Giovanni Francesco;NUNNARI, Giuseppe;
2017-01-01
Abstract
E/C/F/TAF recently approved for treatment of HIV infection,seems to be one of the most appealing combinations,due to his efficacy, durability and tolerability. The available data from clinical trials, showed challenging results about modifications in lipid profile, in particular when switching from TDF to TAF.Data deriving from real-life are missing.Aim of our study was to investigate the role of E/C/F/TAF on lipid profile, within the Italian Compassionate Use program.File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
